ERBB2 and breast carcinoma: Targeted treatment of HER-2 overexpressing breast cancers, like luminal B or HER-2-positive/ER-negative carcinomas, with trastuzumab (Herceptin), either concurrent or sequential with adjuvant chemotherapy, has enhanced survival for patients with these breast cancer subtypes [12,13].